Even countries suspending AstraZeneca's COVID-19 vaccine say there's no proof of blood clot risk
Ireland and the Netherlands late Sunday joined Iceland, Denmark, Norway, and a few other European countries in suspending inoculations with the COVID-19 vaccine developed by AstraZeneca and Oxford University, pointing to reports of serious blood clotting in Norway among a handful of people who received the AstraZeneca vaccine. Irish and Dutch medical authorities stressed that this is a temporary precautionary measure and there is no evidence that Norway's four cases of blood clotting, including one death, were linked to the vaccine.
The European Union's drugs regulator and World Health Organization have also said no data suggests a link between the AstraZeneca vaccine and an increased risk of blood clots. In a statement Sunday night, AstraZeneca said "the safety of the public will always come first " and it is "keeping this issue under close review, but available evidence does not confirm that the vaccine is the cause."
A review of the 17 million people in Europe and the U.K. who have already received the vaccine found 15 cases of deep vein thrombosis and 22 pulmonary embolisms, AstraZeneca said, adding those numbers are "much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
AstraZeneca is right about the lack of any statistically significant risk, Cambridge University statistician David Spiegelhalter writes in The Guardian. "Some anxiety about a new vaccine is understandable, and any suspected reactions should be investigated," but correlation is not the same as causation and "so far, these vaccines have shown themselves to be extraordinarily safe. In fact, it's perhaps surprising that we haven't heard more stories of adverse effects. There could well be some extremely rare event that is triggered by COVID-19 vaccines, but there is no sign of this yet."
The vaccine has not yet been approved by the U.S. Food and Drug Administration.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Katespiracy: is the media to blame?
Talking Point Public statement about cancer diagnosis followed weeks of wild speculation and conspiracy theories
By Julia O'Driscoll, The Week UK Published
-
'Restoring life to an ancient watershed'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
Crossword: March 26, 2024
The Week's daily crossword
By The Week Staff Published
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published
-
Feds cap credit card late fees at $8
speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
By Peter Weber, The Week US Published
-
Immigration helped the US economy outpace peers
speed read The U.S. economy grew at an annualized rate of 3.2% last quarter
By Peter Weber, The Week US Published
-
4-day workweek gets boost from UK study
Speed Read Following a six-month trial, the majority of participating British companies are still using the truncated schedule
By Peter Weber, The Week US Published
-
US sues to block Kroger-Albertsons merger
Speed Read The Federal Trade Commission sued to block the $24.6 billion merger between the grocery giants
By Peter Weber, The Week US Published
-
Nvidia sees historic stock rise on AI chips success
Speed Read U.S. chipmaker Nvidia achieved the biggest one-day increase in value of any company in history
By Peter Weber, The Week US Published
-
New York may seize Trump's assets for $450M penalty
Speed Read The former president likely owes $600 million from two civil judgments in New York
By Peter Weber, The Week US Published